NCT07766980 Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
| NCT ID | NCT07766980 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Florida |
| Condition | Duchenne Muscular Dystrophy |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-07-27 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-07-27 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue).
Eligibility Criteria
Inclusion Criteria: * Diagnosis of DMD confirmed by genetic report * Age 8 years or older. * Stable glucocorticoid and/or other medication regimen for at least 3 months before enrollment and throughout study participation. Exclusion Criteria: * Unstable medical conditions or significant concomitant illness. * Secondary condition affecting muscle function or metabolism (e.g., myasthenia gravis, endocrine disorders, mitochondrial disease). * Participation in another investigational clinical trial within the previous 3 months.
Contact & Investigator
Tanja Taivassalo, MD
PRINCIPAL INVESTIGATOR
University of Florida
Frequently Asked Questions
Who can join the NCT07766980 clinical trial?
This trial is open to male participants only, aged 6 Years or older, studying Duchenne Muscular Dystrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07766980 currently recruiting?
Yes, NCT07766980 is actively recruiting participants. Contact the research team at ttaivassalo@ufl.edu for enrollment information.
Where is the NCT07766980 trial being conducted?
This trial is being conducted at Gainesville, United States.
Who is sponsoring the NCT07766980 clinical trial?
NCT07766980 is sponsored by University of Florida. The principal investigator is Tanja Taivassalo, MD at University of Florida. The trial plans to enroll 20 participants.